Byooviz (ranibizumab-nuna), First Biosimilar to Treat Macular Degeneration Disease and Other Eye Conditions
21 Settembre 2021
The FDA has approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye diseases and conditions, including neovascular
